Yuhan Corporation
Yuhan Corporation is a South Korea-based pharmaceutical company that leads 3 cancer trials in OnCo, testing the immuno-oncology candidates YH32364, YH32367 and YH42946 in non-small-cell lung cancer and advanced solid tumours.
Overview
Yuhan Corporation is a South Korean pharmaceutical company founded in 1926 that makes prescription medicines, health supplements, household and animal health products. Its research pipeline includes the lung cancer drug lazertinib and immuno-oncology candidates such as YH32364 and YH32367. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT06616766 (phase 1/2, A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK an...), NCT06975410 (phase 1/2, Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpr...) and NCT05523947 (phase 1/2, Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.